MetaVia is trading at $1.52 (+5.56%) in pre-market, with no clear company-specific catalyst identified.

  • No clear company-specific catalyst was identified for August 21, 2026.
  • MetaVia’s latest reported event was its August 6, 2026, second-quarter update, including a $5.3 million net loss and clinical progress for DA-1726; it appears stale rather than a fresh overnight trigger.
  • Nasdaq futures are up 0.59%, but broader positive sentiment does not fully explain the move.